Showing 1521-1530 of 1774 results for "".
- Wolfe Eye Clinic Performs First Surgery in Clinical Trial Evaluating an Investigational Gene Therapy for Geographic Atrophy Secondary to Dry AMDhttps://modernod.com/news/wolfe-eye-clinic-performs-first-surgery-in-clinical-trial-evaluating-an-investigational-gene-therapy-for-geographic-atrophy-secondary-to-dry-amd/2478676/Wolfe Eye Clinic announced today that Jared Nielsen, MD, Retina Disease Specialist at Wolfe Eye Clinic, was recently the third surgeon in the United States and first in the Midwest to perform surgery in a clinic trial evaluating an i
- Nicox Partners Zerviate in the Gulf and Arab Marketshttps://modernod.com/news/nicox-partners-zerviate-in-the-gulf-and-arab-markets/2478152/Nicox SA announced the signature of an exclusive license agreement with Itrom Pharmaceutical Group for the registration and commercialization of Zerviate (cetirizine ophthalmic solution), 0.24% for the treatment of ocular itching associated with allergic conjunctivitis in Gulf and Arab markets. I
- Methotrexate Treat-and-Extend Tested for Vitreoretinopathyhttps://modernod.com/news/methotrexate-treat-and-extend-tested-for-vitreoretinopathy/2478096/A treat-and-extend regimen of methotrexate can be used to successfully treat proliferative vitreoretinopathy, according to a series of 50 eyes in which 96% of retinas were successfully reattached, Medscape reported. “I’
- FDA Issues Emergency Use Authorization for Potential COVID-19 Treatmenthttps://modernod.com/news/fda-issues-emergency-use-authorization-for-potential-covid-19-treatment/2477695/The FDA issued an emergency use authorization for the investigational antiviral drug remdesivir for the treatment of suspected or laboratory-confirmed COVID-19 in adults and children hospitalized with severe disease. While there is limited i
- Nicox Signs Agreement for Zerviate in South Koreahttps://modernod.com/news/nicox-signs-agreement-for-zerviate-in-south-korea/2477143/Nicox announced the signature of an exclusive license agreement with Samil Pharmaceutical for the development and commercialization of Zerviate (cetirizine ophthalmic solution) 0.24% for the treatment of ocular itching associated with allergic conjunctivitis in South Korea. Samil Pharmaceutical i
- Amneal Receives FDA Approval for Prednisolone Acetate Ophthalmic Suspensionhttps://modernod.com/news/amneal-receives-fda-approval-for-prednisolone-acetate-ophthalmic-suspension/2482847/Amneal Pharmaceuticals announced the FDA approval of prednisolone acetate ophthalmic suspension 1% sterile, which references Pred Forte (Allergan, an AbbVie company). Launch of the product is planned for the third quarter of 2025. Prednisolone acetate ophthalmic suspension USP 1% i
- CoFi Reaches New Milestone: 10,000 Vision Providers are Now Active on CoFi’s Multi-Party Payment Platformhttps://modernod.com/news/cofi-reaches-new-milestone-10000-vision-providers-are-now-active-on-cofis-multi-party-payment-platform/2482648/CoFi announced it has reached a new milestone of more than 10,000 ophthalmologists and optometrists active on the CoFi platform. Since CoFi’s commercial launch in the summer of 2021, the company has been growing rapidly, with nearly 200 new vision practices joining the platform each month i
- AlloVir and Kalaris Announce Merger to Create Company Focused on Retina Diseasehttps://modernod.com/news/allovir-and-kalaris-therapeutics-announce-agreement-for-transformational-merger-to-create-company-focused-on-diseases-of-the-retina/2482532/AlloVir announced that it has entered into a definitive merger agreement to combine with Kalaris Therapeutics in an all-stock transaction. "On behalf of the AlloVir board, I am thrilled that we have entered into this transformational merger agreement with Kalaris,”
- CASExGLOBAL Launches First AI-Powered Site Management Organizationhttps://modernod.com/news/casexglobal-lauches-first-ai-powered-site-management-organization/2482484/The Centers for Advanced Surgical Exploration (CASExGLOBAL) announced a new partnership with Clinical AI and iOR Partners to introduce what it is calling the first AI-powered site management organization (SMO) and bring clinical trials to ophthalmic office-based surgery (OBS) centers. i
- Neuro-Optometric Rehabilitation Association Appoints Barbara Barclay as New Executive Directorhttps://modernod.com/news/neuro-optometric-rehabilitation-association-appoints-barbara-barclay-as-new-executive-director/2482455/The Neuro-Optometric Rehabilitation Association, International (NORA), has announced the appointment of Barbara Barclay as its new executive director, effective October 1. Ms. Barclay, an expert in eye-tracking technology and health tech, brings more than 30 years of leadership experience, i